Product category:
Antibodies
News Release from: BAC Bio Affinity Company
Edited by the Laboratorytalk Editorial
Team on 04 May 2007
Collaboration for FVIII purification
media
BAC has entered into a collaboration with GE Healthcare to develop and market affinity chromatography media for the purification of therapeutic recombinant FVIII
BAC will provide its CaptureSelect affinity ligands, renowned for their high stability and specificity, to enable efficient process-scale purification of FVIII for the prevention and treatment of bleeding in patients with Haemophilia A CaptureSelect ligands exploit the nature of Camelid single chain antibody fragments and offer enhanced stability and broad antigen-specific binding compared to traditional affinity ligands
This article was originally published on Laboratorytalk on 4 May 2007 at 8.00am (UK)
Related stories
Vaccine purification deal with Sanofi Pasteur
BAC's CaptureSelect customised affinity ligands have been selected by Sanofi Pasteur as they potentially offer high stability and specificity for process-scale purification of some vaccine products
These affinity ligands are manufactured using a high-yielding proprietary yeast-based expression system, which is completely animal-free.
BAC says it can rapidly discover and develop CaptureSelect ligands for chromatographic separations that can be customised for use in the manufacture of a range of biopharmaceuticals, including recombinant proteins, antibodies, antibody fragments and viruses.
"We are extremely pleased that GE Healthcare wishes to further develop and distribute our recombinant FVIII purification ligand products," commented Laurens Sierkstra, CEO of BAC.
"This agreement endorses our technology and extends its accessibility to GE's customers worldwide.".
• BAC Bio Affinity Company: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
